Adagene/$ADAG
Adagene shares are trading higher after the company presented updated data from a study of its drug Muzastotug with KEYTRUDA® at the ASCO Annual Meeting.
3 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Adagene
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.
Ticker
$ADAG
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
138
ISIN
US0053291078
Website
Adagene Metrics
BasicAdvanced
$77M
-
-$0.74
0.50
-
Price and volume
Market cap
$77M
Beta
0.5
52-week high
$3.20
52-week low
$1.33
Average daily volume
15K
Financial strength
Current ratio
2.299
Quick ratio
2.231
Long term debt to equity
1.108
Total debt to equity
36.604
Interest coverage (TTM)
-42.20%
Management effectiveness
Return on assets (TTM)
-21.92%
Return on equity (TTM)
-55.21%
Valuation
Price to revenue (TTM)
709.297
Price to book
1.52
Price to tangible book (TTM)
1.52
Price to free cash flow (TTM)
-2.461
Growth
Revenue change (TTM)
-99.43%
Earnings per share change (TTM)
69.66%
3-year revenue growth (CAGR)
-78.35%
3-year earnings per share growth (CAGR)
-25.96%
What the Analysts think about Adagene
Analyst ratings (Buy, Hold, Sell) for Adagene stock.
Adagene Financial Performance
Revenues and expenses
Adagene Earnings Performance
Company profitability
Adagene News
AllArticlesVideos
Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewsWire·22 hours ago
Adagene Appoints John Maraganore, Ph.D. as Executive Advisor
GlobeNewsWire·4 weeks ago
Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Adagene stock?
Adagene (ADAG) has a market cap of $77M as of May 23, 2025.
What is the P/E ratio for Adagene stock?
The price to earnings (P/E) ratio for Adagene (ADAG) stock is 0 as of May 23, 2025.
Does Adagene stock pay dividends?
No, Adagene (ADAG) stock does not pay dividends to its shareholders as of May 23, 2025.
When is the next Adagene dividend payment date?
Adagene (ADAG) stock does not pay dividends to its shareholders.
What is the beta indicator for Adagene?
Adagene (ADAG) has a beta rating of 0.5. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.